USE OF PROTEASE INHIBITORS AND GRF MOLECULES IN COMBINATION THERAPY
Combination therapies comprising a protease inhibitor and a growth hormone (GH)-inducing compound (such as a GRF molecule) are described, in which there are no or substantially no drug interactions.
1 . A method of inducing GH levels in a subject undergoing an antiretroviral protease inhibitor treatment regimen or who is a candidate for an antiretroviral protease inhibitor treatment regimen, without modifying said treatment regimen, said method comprising administering to said subject an effective amount of (hexenoyl trans-3)hGRF(1-44)NH 2 .
2 . A method of treating excess abdominal fat in a HIV-infected subject with lipodystrophy, wherein said subject is undergoing an antiretroviral protease inhibitor treatment regimen or is a candidate for an antiretroviral protease inhibitor treatment regimen, without substantially modifying said treatment regimen, said method comprising administering to said subject an effective amount of (hexenoyl trans-3)hGRF(1-44)NH 2 .
3 . The method of claim 1 , further comprising, prior to said treating, selecting a subject who is undergoing, or who is a candidate for, an antiretroviral protease inhibitor treatment regimen.
4 . The method of claim 2 , further comprising, prior to said treating, selecting a subject who is undergoing, or who is a candidate for, an antiretroviral protease inhibitor treatment regimen.
5 . A method comprising providing information to a subject or to a caregiver of the subject that (hexenoyl trans-3)hGRF(1-44)NH 2 and a protease inhibitor can be co-administered to the subject.
6 . The method of claim 5 , further comprising providing information to the subject or to the caregiver of the subject that (hexenoyl trans-3)hGRF(1-44)NH 2 can be co-administered to the subject without affecting pharmacokinetics of said protease inhibitor.
7 . The method of claim 5 , further comprising providing information to the subject or to the caregiver of the subject that (hexenoyl trans-3)hGRF(1-44)NH 2 can be co-administered to the subject without modifying the treatment regimen of said protease inhibitor.
8 . The method of claim 5 , further comprising selecting a subject who is undergoing or who is a candidate for a treatment regimen with (hexenoyl trans-3)hGRF(1-44)NH 2 and with a protease inhibitor.
9 . The method of claim 1 , wherein the protease inhibitor is ritonavir.
10 . The method of claim 1 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered at a daily dose of about 2 mg.
11 . The method of claim 1 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered subcutaneously.
12 . The method of claim 2 , wherein the protease inhibitor is ritonavir.
13 . The method of claim 2 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered at a daily dose of about 2 mg.
14 . The method of claim 2 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered subcutaneously.
15 . The method of claim 5 , wherein the protease inhibitor is ritonavir.
16 . The method of claim 5 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered at a daily dose of about 2 mg.
17 . The method of claim 5 , wherein the (hexenoyl trans-3)hGRF(1-44)NH 2 is administered subcutaneously.